Skip to content
Lower risk Drug recall · FDA · Published June 18, 2024

Major Pharmaceuticals 37.5mg Venlafaxine Capsules Recall: Failed Dissolution Testing

Major Pharmaceuticals recalls 37.5mg Venlafaxine Hydrochloride extended-release capsules due to failed dissolution testing during stability checks. This medication is prescription-only and may not release properly in the body.

🇺🇸 FDA recall #D-0584-2024DrugMajor Pharmaceuticals ›
Take action

Contact the company

Recalling firmThe Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories341 Mason Rd · La Vergne, TN 37086-3606
✎ GovInfoNow plain-language explainer

What happened, in plain English

Major Pharmaceuticals is recalling 37.5mg Venlafaxine Hydrochloride extended-release capsules because they failed dissolution testing during routine stability checks. This means the capsules might not release medication properly in the body, potentially affecting treatment effectiveness. Read more at govinfonow.com/recall/32627-major-pharmaceuticals-37-5mg-venlafaxine-capsules-recall-failed-dissolution-testing.

Source Summary by GovInfoNow · govinfonow.com/recall/32627-major-pharmaceuticals-37-5mg-venlafaxine-capsules-recall-failed-dissolution-testing · Updated August 17, 2026 · FDA enforcement record: FDA #D-0584-2024

Cite this page

“Major Pharmaceuticals 37.5mg Venlafaxine Capsules Recall: Failed Dissolution Testing.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/32627-major-pharmaceuticals-37-5mg-venlafaxine-capsules-recall-failed-dissolution-testing. Based on FDA recall #D-0584-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0584-2024%22&limit=1).

Why it’s dangerous

The capsules failed dissolution testing during routine stability checks, meaning they may not release medication properly in the body. This could affect how well the medication works for patients who need it for mental health conditions.

Who’s affected

Prescription patients who received this specific 37.5mg Venlafaxine Hydrochloride extended-release capsule product from Major Pharmaceuticals. Those with mental health conditions requiring this medication are most at risk.

How to tell if you have this one

Look for the product labeled 'Venlafaxine Hydrochloride, extended-release capsules, USP, 37.5mg, 10 x 10 blister card in one carton, Rx only'. The NDC code is 0904-7075-61 and it was manufactured with lot code M04614, expiring September 30, 2024.

  • Brand
    Major Pharmaceuticals
  • Product
    Venlafaxine Hydrochloride, extended-release capsules, USP, 37.5mg, 10 x 10 blister card in one carton, Rx only, Mfg by
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Verify the NDC code 0904-7075-61 and lot code M04614 on the packaging to confirm if this product is affected.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide. No foreign consignees.” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 18 months after the firm started it.

1. Firm started the recall: Jun 18, 202412. FDA classified it Class II: Jul 3, 202423. Published in FDA’s Enforcement Report: Jul 10, 202434. FDA terminated the recall: Dec 22, 2025420242025
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0584-2024 (June 18, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0584-2024 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA